Danish obesity and diabetes drugmaker Novo Nordisk A/S is set to acquire the Singapore-based KBP Biosciences Co. Ltd.’s hypertension drug, ocedurenone (KBP-5074), for potentially $1.3 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback